Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

• Asıl Yazarlar: Jinjin Wang (Yazar), Ailin Zhao (Yazar), Hui Zhou (Yazar), Jinbing Zhu (Yazar), Ting Niu (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2020-11-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Background: Ibrutinib is an oral covalent Bruton's tyrosine kinase inhibitor that has been approved for chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia and some other B-cell malignancies. Some studies have found an increased risk of bleeding with ibrutinib. Some studies, however,...